Immunic is the specialist for selective oral drugs in immunology. As a clinical stage company, we deliver clinical proof-of-concept for best-in-class therapies of chronic inflammatory and autoimmune diseases.
Immunic AG is based in the Munich biotech hub Martinsried and currently develops three products for the treatment of chronic inflammatory diseases including e.g. IBD and psoriasis. IMU-838 will be tested in a phase IIb trial in patients suffering from ulcerative colitis beginning of 2018. IMU-366 is a best-in-class inverse agonist of the nuclear receptor ROR gamma-t and currently in advanced preclinical stage.